Source link : https://www.newshealth.biz/health-news/fda-approves-mesenchymal-stromal-cell-therapy-for-refractory-acute-gvhd-in-kids/
Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light. The approval of remestemcel-L (Ryoncil) specifies use in pediatric patients 2 months or older with steroid-refractory acute GVHD. The cellular therapy received a vote of confidence from […]
Author : News Health
Publish date : 2024-12-19 17:27:00
Copyright for syndicated content belongs to the linked Source.